Measure
Set
Title/Number
Assessment of Psoriasis
Disease Activity
Type
Process
Denominator
Numerator
All patients with a diagnosis of plaque
psoriasis.
Patients with disease activity assessed by a standardized descriptive or numeric scale
or composite index.*
*Assessment and classification of disease activity: Scales and instruments are
examples and cut-off points can differ by scale. Standardized descriptive or numeric
scales and/or composite indexes could include but are not limited to: Psoriasis Area
and Severity Index (PASI), Body Surface Area (BSA), Physician’s Global
Assessment (PGA), Dermatology Life Quality Index (DLQI).
Psoriasis
Numerator Instructions: To satisfy this measure, psoriasis activity should be
measured using any of the above or other scales or instruments at least once during
the reporting period for each patient with a diagnosis of plaque psoriasis who
presents for an office visit.
Assessment for Psoriatic
Arthritis
MUC 136/MAPX3274
Process
All patients with a diagnosis of
psoriasis.
Patients who are “screened”* for psoriatic arthritis.
* “Screening” for psoriatic arthritis must, at a minimum, include inquiry about the
presence or absence of joint symptoms including any of the following: morning
stiffness, pain, redness, and/or swelling of joints. If a dermatologist wishes to
perform additional optional screening measures, these may include physical
examination (e.g. visualization of joints, surrounding structures (entheses) and
fingers/toes for dactylitis) and/or use of a validated psoriatic arthritis screening
instrument (Psoriatic Arthritis Screening and Evaluation), ToPAS (Toronto Psoriatic
Arthritis Screening) or PEST (Psoriasis Epidemiology Screening Tool).
Numerator Instructions: To satisfy this measure, presence or absence of joint
symptoms should be documented at least once during the reporting period.
American Academy of Dermatology
June 19, 2015
Tuberculosis Prevention
for Psoriasis, Psoriatic
Arthritis and
Rheumatoid Arthritis
Patients on a Biological
Immune Response
Modifier
PQRS 337
Process
All patients with a diagnosis of
psoriasis, psoriatic arthritis, or
rheumatoid arthritis who are on a
biologic immune response modifier.
Patients who have a documented negative annual TB screening or have
documentation of the management of a positive TB screening test with no evidence
of active tuberculosis, confirmed through use of radiographic imaging (i.e. chest xray, CT).
Denominator Note: A patient would
be considered denominator eligible for
Measure #337 for reporting purposes,
if the patient meets the denominator
criteria with diagnosis of psoriasis or
psoriatic arthritis or rheumatoid
arthritis AND is on a biologic immune
response modifier prescribed by the
provider being evaluated for the
measure.
Clinical Response to
Oral Systemic or
Biologic Medications
MUC 134/MAP X3726
Outcome
All patients with a diagnosis of
psoriasis and treated with an oral
systemic or biologic medication for
psoriasis for at least 6 months.
Patients who have a documented physician global assessment (PGA; 6-point scale),
body surface area (BSA), psoriasis area and severity index (PASI) and/or
dermatology life quality index (DLQI) that meet any one of the below specified
benchmarks.
Numerator Instructions: To satisfy this measure, a patient must achieve any ONE
of the following:
a. PGA (6-point scale) ˂ 2 (clear to mild skin disease)
b. BSA < 3% (mild disease)
c. PASI < 3 (no or minimal disease)
d. DLQI < 5 (no effect or small effect on patient’s quality of life).
American Academy of Dermatology
June 19, 2015